-
All Resources
(choose a category)
-
All Resources
-
selected
Evidence
Evidence, advice, guidance and standards
-
Improvement
Improvement and implementation support
-
selected
Scrutiny
Assurance, scrutiny, measurement and reporting
-
-
Healthcare Area
- Blood and immune system
- Cancer
- Cardiovascular system
- Dermatology
- Digestive system
- Ear, nose and throat
- Endocrine, nutritional and metabolic
- Eye
- Genitourinary system
- Infectious disease
- Injuries, accidents and wounds
- Mental and behavioural disorders
- Mouth and dental
- Musculoskeletal system
- Nervous system
- Obstetrics and gynaecology
- Respiratory system
-
Resource Type
- NICE Guidance
- Programme
- Year
- prev
- Page 9 of 3
28 results found filtered by Evidence Remove Evidence Filter Scrutiny Remove Scrutiny Filter 2010 Remove 2010 Filter 2008 Remove 2008 Filter NICE Guidance Remove NICE Guidance Filter Clear Search
-
Appraisal 210 'Clopidogrel and modified-release dipyridamole
- Published
- 15 December 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 211 – Prucalopride for the treatment of chronic constipation in women
- Published
- 15 December 2010
- Cycle of Improvement
- Evidence
-
Appraisal 209 Imatinib for the treatment of unresectable and metastatic gastrointestinal stromal tumours
- Published
- 24 November 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 208 – Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
- Published
- 24 November 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 201 Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 202 Ofatumumab for the treatment of refractory chronic lymphocytic leukaemia
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 207 – Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated ap
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No. 204 Denosumab for the prevention of osteoporotic fractures
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance no. 205 Eltrombopag for treatment of thrombocytopenic purpura
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 206 – Bendamustine for the treatment of indolent (low grade) non-Hodgkin’s lymphoma that is refrac
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence